Oral anticoagulation for the antiphospholipid antibody syndrome: can we now say less is more?
Anderson
D R
DR
Department of Medicine, Dalhousie University and Capital Health, Halifax, Nova Scotia, Canada. david.anderson@dal.ca
D000284:Administration, Oral; D017152:Antibodies, Antiphospholipid / Q000737:chemistry*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D016736:Antiphospholipid Syndrome / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D016682:Lupus Coagulation Inhibitor / Q000494:pharmacology; D008297:Male; D012189:Retrospective Studies; D012306:Risk; D013923:Thromboembolism / Q000188:drug therapy; D020246:Venous Thrombosis / Q000188:drug therapy*; D014859:Warfarin / Q000627:therapeutic use
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D016682:Lupus Coagulation Inhibitor; D014859:Warfarin; D001241:Aspirin